Moderna Adjusts Operating Model to Support Business Goals
Moderna (MRNA) announced changes to its operating model to support its short- and long-term business goals. As Moderna executes its long-range plan to become a diversified, multi-modality biotechnology company, the Company is preparing to manage three commercial franchises while advancing a broad mRNA pipeline and investing in Moderna research and early development. Building on momentum in its infectious disease vaccine business with four approved products, Moderna is anticipating the potential launch of up to three new products in 2027 and 2028, including flu plus COVID combination, seasonal flu and norovirus vaccines. At the same time, the Company expects important clinical milestones this year, including potential pivotal data readouts for its investigational individualized neoantigen therapy and rare genetic disease propionic acidemia therapeutic, which could support the possible launch of its first oncology and rare disease products. To support this next phase of growth, Stephen Hoge, President of Moderna, will assume oversight of operational and cross-functional leadership across Research & Development, Manufacturing and Commercial for the Company's three franchises. In this expanded role, Hoge will help ensure strategic alignment across the business, strengthen enterprise execution, and accelerate Moderna's ability to deliver innovative medicines to patients around the world. As part of this evolution, Ester Banque has been appointed as the Company's Chief Commercial Officer. In this role, she will focus on continuing to build out Moderna's global commercial organization, leading execution across product launches, and expanding the Company's presence in new markets. Ms. Banque will serve on Moderna's Executive Committee and report to CEO Stephane Bancel. Most recently, Banque served as Executive Vice President and President, U.S. Operations at Zoetis (ZTS).
